1H NMR-based metabolic profiling of naproxen-induced toxicity in rats

Toxicology Letters

Volumn 200, Issue 1-2, 2011, Pages 1-7

  Jung, Jeeyoun ^a,b   Park, Minhwa ^a   Park, Hye Jin ^c   Shim, Sun Bo ^c   Cho, Yang Ha ^c   Kim, Jinho ^c   Lee, Ho Sub ^b   Ryu, Do Hyun ^d   Choi, Donwoong ^c   Hwang, Geum Sook ^a,e  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Wonkwang University   (South Korea)

^c National Institute of Food and Drug Safety Evaluation   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Chungnam National University   (South Korea)

Author keywords

Drug toxicity; Gastrointestinal damage; Metabolomics; Naproxen; NMR

Indexed keywords

ACONITIC ACID; BETAINE; CHOLINE; CITRIC ACID; CREATINE; CREATINE PHOSPHATE; FIBROBLAST GROWTH FACTOR 1; KYNURENIC ACID; NAPROXEN; TRYPTOPHAN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DECOMPOSITION; DOSE RESPONSE; DRUG MEGADOSE; ENERGY METABOLISM; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STOMACH MUCOSA; STOMACH ULCER; TOXICITY TESTING; ULCER HEALING; URINE LEVEL;

ANIMALS; CHOLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; GLYCINE; HYDROXYBUTYRATES; KYNURENIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NAPROXEN; PANTOTHENIC ACID; PHOSPHOCREATINE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH; TRYPTOPHAN;

RATTUS;

EID: 78650173031     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.09.020     Document Type: Article

References (40)

1. Andreeshcheva E.M., Popova T.N., Artyukhov V.G., Matasova L.V. Free radical oxidation and catalytic activity of aconitate hydratase in rat liver under normal conditions and during toxic hepatitis. Bull. Exp. Biol. Med. 2004, 137:352-354.
2. Appleyard C.B., McCafferty D.M., Tigley A.W., Swain M.G., Wallace J.L. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am. J. Physiol. 1996, 270:G42-G48.
3. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343:1520-1528.
4. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., Vidal J.M., Van De Vorstenbosch C. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 2001, 21:15-23.
5. Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wold, S., 2001. Multi-and megavariate data analysis. Umetrics Umea, Sweden.
6. 1H-NMR-based metabonomics. Am. J. Physiol. Renal Physiol. 2009, 298:F461-F470.
7. Goodacre R., Vaidyanathan S., Dunn W.B., Harrigan G.G., Kell D.B. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004, 22:245-252.
8. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J. Clin. Gastroenterol. 1990, 12:10-13.
9. Kato S., Takeuchi K. Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. Jpn. J. Pharmacol. 2002, 89:1-6.
10. Kim K.B., Chang M.S., Chung Y.K., Sohn S.K., Kim S.G., Choi W.S. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl) amino] quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats. J. Pharm. Pharmacol. 1998, 50:521-529.
11. Konturek P.C., Konturek S.J., Celinski K., Slomka M., Cichoz-Lach H., Bielanski W., Reiter R.J. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J. Pineal. Res. 2010, 48:318-323.
12. Kurinets A., Lichtenberger L.M. Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. Dig. Dis. Sci. 1998, 43:786-790.
13. Lanza F.L., Royer G.L., Nelson R.S., Chen T.T., Seckman C.E., Rack M.F. The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study. Dig. Dis. Sci. 1979, 24:823-828.
14. Larkai E.N., Smith J.L., Lidsky M.D., Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am. J. Gastroenterol. 1987, 82:1153-1158.
15. Lin H.M., Barnett M.P.G., Roy N.C., Joyce N.I., Zhu S., Armstrong K., Helsby N.A., Ferguson L.R., Rowan D.D. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J. Proteome Res. 2010, 9:1965-1975.
16. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4:762-774.
17. Miura T., Muraoka S., Fujimoto Y. Inactivation of creatine kinase during the interaction of indomethacin with horseradish peroxidase and hydrogen peroxide: involvement of indomethacin radicals. Chem. Biol. Interact. 2001, 134:13-25.
18. Moreno-Sánchez R., Bravo C., Vásquez C., Ayala G., Silveira L.H., Martínez-Lavín M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57:743-752.
19. Moroni F., Russi P., Lombardi G., Beni M., Carlà V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 1988, 51:177-180.
20. Morvan D., Demidem A. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res. 2007, 67:2150-2159.
21. Nervi F. Significance of biliary phospholipids for maintenance of the gastrointestinal mucosal barrier and hepatocellular integrity. Gastroenterology 2000, 118:1265-1267.
22. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
23. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
24. Peters A. The energy request of inflammation. Endocrinology 2006, 147:4550-4558.
25. Rainsford K.D., Whitehouse M.W. Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs. Biochem. Pharmacol. 1980, 29:1281-1289.
26. Schwieler L., Erhardt S., Erhardt C., Engberg G. Prostaglandin-mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J. Neural Transm. 2005, 112:863-872.
27. Serio C.D., Cozzi A., Angeli I., Doria L., Micucci I., Pellerito S., Mirone P., Masotti G., Moroni F., Tarantini F. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol. Neurobiol. 2005, 25:981-993.
28. Silvoso G.R., Ivey K.J., Butt J.H., Lockard O.O., Holt S.D., Sisk C., Baskin W.N., Mackercher P.A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann. Intern. Med. 1979, 91:517-520.
29. Somasundaram S., Hayllar H., Rafi S., Wrigglesworth J.M., Macpherson A.J.S., Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand. J. Gastroenterol. 1995, 30:289-299.
30. Somasundaram S., Rafi S., Hayllar J., Sigthorsson G., Jacob M., Price A.B., Macpherson A., Mahmod T., Scott D., Wrigglesworth J.M., Bjarnson I. Mitochondrial damage: a possible mechanism of the " topical" phase of NSAID induced injury to the rat intestine. Gut 1997, 41:344-353.
31. Takeuchi K., Ueki S., Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig. Dis. Sci. 1986, 31:1114-1122.
32. Tanaka A., Araki H., Komoike Y., Hase S., Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 2001, 95:21-27.
33. Tarnawski A.S., Jones M.K. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J. Mol. Med. 2003, 81:627-636.
34. 1H NMR-based metabolomics in rats. Anal. Chem. 2009, 81:4734-4741.
35. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231:232-235.
36. Wallace J.L. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage--potential for development of gastrointestinal tract safe NSAIDs. Can. J. Physiol. Pharmacol. 1994, 72:1493-11493.
37. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. 1990, 259:G462-G467.
38. Wang D., Mayo M.W., Baldwin A.S. Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. Oncogene 1997, 14:2291-2299.
39. Whittle B.J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981, 80:94-98.
40. Whittle B.J.R. Unwanted Effects of Aspirin and Related Agents on the Gastrointestinal Tract. Aspirin and Other Salicylates 1992, Chapman & Hall Medical, London, pp. 465-509.